Free tool
FAERS Monitor: Krintafel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210795 or its brand name (Krintafel, Tafenoquine Succinate). Reports on generic versions are filed under their own applications.
Reports
11
Serious
7
64% of reports
Hospitalization
5
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3
- off label use3
- bacteraemia2
- blood fibrinogen decreased2
- blood lactate dehydrogenase increased2
- blood triglycerides increased2
- candida infection2
- drug effective for unapproved indication2
- haemolysis2
- haemolytic anaemia2
- haemophagocytic lymphohistiocytosis2
- infection2
- lactic acidosis2
- leukoerythroblastosis2
- malaria2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,148 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| leukoerythroblastosis | 2 | 39061.5 | 10978.9 | 43,063 |
| malaria | 2 | 5445.3 | 1551.1 | 6,106 |
| blood fibrinogen decreased | 2 | 3357.9 | 957.3 | 3,768 |
| haemophagocytic lymphohistiocytosis | 2 | 509.7 | 145.5 | 570 |
| haemolysis | 2 | 495.3 | 141.4 | 554 |
| haemolytic anaemia | 2 | 426.9 | 121.9 | 477 |
| bacteraemia | 2 | 322.4 | 92.0 | 360 |
| blood lactate dehydrogenase increased | 2 | 241.3 | 68.9 | 269 |
| candida infection | 2 | 226.5 | 64.6 | 252 |
| blood triglycerides increased | 2 | 216.5 | 61.8 | 241 |
| drug effective for unapproved indication | 2 | 130.6 | 37.3 | 144 |
| lactic acidosis | 2 | 118.1 | 33.7 | 130 |
| infection | 2 | 26.4 | 7.5 | 27 |
| off label useSignal | 3 | 6.6 | 2.5 | 10 |
| drug ineffectiveSignal | 3 | 4.4 | 1.7 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.